Literature DB >> 16635603

A prospective registry to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions using the "crush technique".

Issam Moussa1, Ricardo A Costa, Martin B Leon, Alexandra J Lansky, Zoran Lasic, Ecaterina Cristea, Nenad Trubelja, Stephane G Carlier, Roxana Mehran, George D Dangas, Giora Weisz, Edward M Kreps, Michael Collins, Gregg W Stone, Jeffrey W Moses.   

Abstract

The "crush technique" has been proposed as an alternative approach to treat bifurcation lesions because of its predictability and high procedural success rate. However, few data are available regarding its safety and long-term efficacy. We report the long-term clinical outcomes of patients with coronary bifurcation lesions treated with sirolimus-eluting stents using the crush technique. From April 2003 to May 2004, 120 patients with coronary bifurcation lesions were treated with sirolimus-eluting stents using the crush technique. Six months of clinical follow-up was completed in 95.8% of patients. Mean patient age was 64 years; 36% had diabetes mellitus, and the left anterior descending artery/diagonal was the most frequent bifurcation location (69%). Final kissing balloon inflation was performed in 87.5% of patients. Compared with the main vessel, side branch lesions were shorter, with a smaller reference diameter and final in-stent minimum lumen diameter. Procedural success was achieved in 97.5%. At 30 days of follow-up, 1 patient had died of noncardiac causes and 2 patients (1.7%) had subacute stent thrombosis. At 6 months of follow-up, target lesion revascularization was required in 13 patients (11.3%), all of whom had focal restenosis predominantly at the side branch ostium. In conclusion, the crush technique with final kissing balloon inflation can be safely used by experienced operators to treat highly complex bifurcation lesions with sirolimus-eluting stents. The safety profile of this technique is similar to that of other bifurcation stenting techniques reported thus far. Nonetheless, despite the excellent patency rates of the main vessel, the need for revascularization at the ostium of the side branch was not fully eliminated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16635603     DOI: 10.1016/j.amjcard.2005.11.072

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Comparison between measured and calculated length of side branch ostium in coronary bifurcation lesions with intravascular ultrasound.

Authors:  Hyeon Min Ryu; Byeong-Keuk Kim; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Yangsoo Jang; Myeong-Ki Hong
Journal:  Yonsei Med J       Date:  2012-07-01       Impact factor: 2.759

Review 2.  Dedicated bifurcation stents.

Authors:  Ajith Ananthakrishna Pillai; Balachander Jayaraman
Journal:  Indian Heart J       Date:  2012-04-28

Review 3.  Vascular smooth muscle cell proliferation in restenosis.

Authors:  Steven O Marx; Hana Totary-Jain; Andrew R Marks
Journal:  Circ Cardiovasc Interv       Date:  2011-02-01       Impact factor: 6.546

Review 4.  Drug eluting stents: focus on Cypher sirolimus-eluting coronary stents in the treatment of patients with bifurcation lesions.

Authors:  Alaide Chieffo; Tiziana Claudia Aranzulla; Antonio Colombo
Journal:  Vasc Health Risk Manag       Date:  2007

5.  Study comparing the double kissing (DK) crush with classical crush for the treatment of coronary bifurcation lesions: the DKCRUSH-1 Bifurcation Study with drug-eluting stents.

Authors:  S L Chen; J J Zhang; F Ye; Y D Chen; T Patel; K Kawajiri; M Lee; T W Kwan; G Mintz; H C Tan
Journal:  Eur J Clin Invest       Date:  2008-06       Impact factor: 4.686

6.  The modified balloon crush technique: A simplified approach to optimizing final kissing balloon inflation.

Authors:  Jae-Hyung Roh; Young-Hak Kim; Hee Jun Kang; Pil Hyung Lee; Sung-Han Yoon; Mineok Chang; Jung-Min Ahn; Duk-Woo Park; Soo-Jin Kang; Seung-Whan Lee; Cheol Whan Lee; Seong-Wook Park; Seung-Jung Park
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.